A carregar...
How we treat neurological toxicity from immune checkpoint inhibitors
Neurological adverse events from immune checkpoint inhibition are increasingly recognised, especially with combination anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) and anti-programmed death receptor 1 (anti-PD-1) therapies. Their presenting symptoms and signs are often subacute and highly variable,...
Na minha lista:
| Publicado no: | ESMO Open |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6678012/ https://ncbi.nlm.nih.gov/pubmed/31423344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000540 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|